Page last updated: 2024-09-04

atrasentan and Diabetic Nephropathies

atrasentan has been researched along with Diabetic Nephropathies in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (2.44)	29.6817
2010's	24 (58.54)	24.3611
2020's	16 (39.02)	2.80

Authors

Authors	Studies
Bakris, G; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Rossing, P; Xie, D	1
Bakris, GL; Correa-Rotter, R; de Zeeuw, D; Gansevoort, RT; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, DE; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Tobe, S; Waijer, SW	1
Fernandez-Fernandez, B; Ortiz, A	1
Bakris, GL; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Januzzi, JL; Kitzman, DW; Kohan, DE; Kolansky, DM; Koomen, J; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Smeijer, JD; Tobe, S	1
Barratt, J; Heerspink, HJL; Kohan, DE; Liew, A; Tang, SCW	1
de Zeeuw, D; Heerspink, HJL; Kohan, DE; Smeijer, JD	1
Iwagami, M	1
de Zeeuw, D; Heerspink, HJL; Parving, HH	1
Walsh, M	1
Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA	1
Chi, J; Dong, B; Huang, Y; Lv, W; Wang, YG; Zhou, Y	1
Bakris, G; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Koomen, JV; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Stevens, J; Tobe, SW	1
Bakris, G; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, DE; Koomen, JV; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Stevens, J; Tobe, SW	1
Andreucci, M; De Nicola, L; Garofalo, C; Minutolo, R; Provenzano, M; Serra, R	1
Baelde, HJ; Bajema, IM; Bos, M; Bruijn, JA; Dijkstra, KL; van Aanhold, CCL; van den Berg, BM; Wolterbeek, R	1
Dhaun, N; Heerspink, HJL; Kohan, DE; Smeijer, JD; Webb, DJ	1
Egido, J; Gomez-Guerrero, C; Gonzalez Parra, E; Mas, S; Rojas-Rivera, J; Ruiz-Ortega, M; Sanz, AB	1
Awni, WM; J Brennan, J; Klein, CE; L Andress, D; Lin, CW; Mostafa, NM	1
Andress, D; Brennan, JJ; Busch, R; Coll, B; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Houser, M; Kohan, D; Makino, H; Parving, HH; Pergola, P; Perkovic, V; Pritchett, Y; Remuzzi, G; Tobe, SW; Toto, R; Webb, DJ	1
Andress, DL; Bakris, G; Brennan, JJ; Correa-Rotter, R; de Zeeuw, D; Dey, J; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, J; Parving, HH; Perkovic, V; Tobe, S; Wigderson, M	1
de Zeeuw, D; Heerspink, HJL; Koomen, JV; Mostafa, NM; Parving, HH; Stevens, J	1
Andress, DL; Bakris, G; Brennan, JJ; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, J; Parving, HH; Perkovic, V; Tobe, S; Wigderson, M; Yi, T	1
Heerspink, HJL; Muskiet, MHA; Wheeler, DC	1
Brenner, S; Wanner, C	1
Nangaku, M	1
Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; de Zeeuw, D; Houser, M; Kohan, D; Lambers Heerspink, HJ; Makino, H; Parving, HH; Perkovic, V; Pritchett, Y; Remuzzi, G; Tang, H; Tobe, SW; Toto, R; Viberti, G	1
Parving, HH; Rossing, P	1
Andress, DL; Bijlsma, MJ; de Zeeuw, D; Heerspink, HJ; Kröpelin, TF; Parving, HH; Persson, F	1
Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; de Zeeuw, D; Hou, FF; Kitzman, DW; Kohan, DE; Lambers Heerspink, HJ; Makino, H; Parving, HH; Perkovic, V; Remuzzi, G; Tobe, SW; Toto, R	1
Kang, WL; Xu, GS	1
Allison, SJ	1
Batu Demir, D; Cooper, ME	1
Avramut, MC; Boels, MG; Dane, MJ; Gröne, HJ; Koster, AJ; Koudijs, A; Lee, DH; Rabelink, TJ; van den Berg, BM; van der Vlag, J; van Faassen, E; van Zonneveld, AJ	1
Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; Davis, JW; de Zeeuw, D; Heerspink, HJ; Idler, K; Kohan, DE; Liu, M; Makino, H; Parving, HH; Perkovic, V; Remuzzi, G; Tobe, SW; Toto, R	1
Breyer, MD; Susztak, K	1
Andress, DL; Audhya, P; Garimella, T; Kohan, DE; Molitch, M; Pritchett, Y; Wen, S	1
Ritz, E; Wenzel, RR	1
Pollock, DM; Pollock, JS; Saleh, MA	1
Kohan, DE; Rabelink, TJ	1
Andress, DL; Brennan, J; Coll, B; Kohan, DE; Molitch, M; Pritchett, Y	1
Carmines, PK; Hobbs, JL; Pollock, DM; Pollock, JS; Sasser, JM; Sullivan, JC; Yamamoto, T	1

Reviews

8 review(s) available for atrasentan and Diabetic Nephropathies

Article	Year
Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Diabetic medicine : a journal of the British Diabetic Association, 2021, Volume: 38, Issue:1 Topics: Albuminuria; Atrasentan; Bosentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Heart Failure; Humans; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic	2021
Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease. Expert opinion on investigational drugs, 2021, Volume: 30, Issue:3 Topics: Animals; Atrasentan; Diabetic Nephropathies; Disease Progression; Endothelin A Receptor Antagonists; Humans; Proteinuria; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Renal Insufficiency, Chronic	2021
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. Current opinion in nephrology and hypertension, 2021, 07-01, Volume: 30, Issue:4 Topics: Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Endothelin Receptor Antagonists; Humans; Renal Insufficiency, Chronic; Renin-Angiotensin System	2021
Atrasentan for the treatment of diabetic nephropathy. Expert opinion on investigational drugs, 2017, Volume: 26, Issue:6 Topics: Animals; Atrasentan; Diabetic Nephropathies; Endothelin Receptor Antagonists; Endothelin-1; Humans; Proteinuria; Pyrrolidines; Renal Insufficiency, Chronic	2017
New pharmacological strategies for protecting kidney function in type 2 diabetes. The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:5 Topics: Antihypertensive Agents; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Incretins; Mineralocorticoid Receptor Antagonists; Naphthyridines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors	2019
New strategies to tackle diabetic kidney disease. Current opinion in nephrology and hypertension, 2016, Volume: 25, Issue:4 Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Pyrrolidines; Renal Artery; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Sympathectomy	2016
Developing Treatments for Chronic Kidney Disease in the 21st Century. Seminars in nephrology, 2016, Volume: 36, Issue:6 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atrasentan; Benzhydryl Compounds; Canagliflozin; Diabetic Nephropathies; Drug Discovery; Endothelin Receptor Antagonists; Glucosides; Glycosaminoglycans; Humans; Hypoglycemic Agents; Mineralocorticoid Receptor Antagonists; Oleanolic Acid; Oxidative Stress; Pyridoxamine; Pyrrolidines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors	2016
Endothelin receptor blockade in patients with diabetic nephropathy. Contributions to nephrology, 2011, Volume: 172 Topics: Atrasentan; Clinical Trials as Topic; Creatinine; Diabetic Nephropathies; Endothelin Receptor Antagonists; Glomerular Filtration Rate; Humans; Pyridines; Pyrimidines; Pyrrolidines; Serum Albumin	2011

Trials

14 trial(s) available for atrasentan and Diabetic Nephropathies

Article	Year
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. Journal of the American Society of Nephrology : JASN, 2021, Volume: 32, Issue:11 Topics: Aged; Albuminuria; Atrasentan; Causality; Creatinine; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Reduction Behavior; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome	2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Clinical journal of the American Society of Nephrology : CJASN, 2021, Volume: 16, Issue:12 Topics: Albuminuria; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Renal Insufficiency; Renal Insufficiency, Chronic	2021
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. JACC. Heart failure, 2022, Volume: 10, Issue:7 Topics: Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Natriuretic Peptide, Brain; Renal Insufficiency, Chronic; Weight Gain	2022
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:2 Topics: Albuminuria; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Humans; Kidney	2021
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:6 Topics: Aged; Area Under Curve; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Treatment Outcome	2021
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. Drugs in R&D, 2017, Volume: 17, Issue:3 Topics: Aged; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Electric Impedance; Endothelin Receptor Antagonists; Female; Humans; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Renin-Angiotensin System; Weight Gain	2017
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:6 Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Precision Medicine; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Severity of Illness Index	2018
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:8 Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Biological Variation, Population; Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Metabolic Clearance Rate; Renal Elimination; Renal Insufficiency; Severity of Illness Index; Sodium	2018
Baseline characteristics and enrichment results from the SONAR trial. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:8 Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diuretics; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Precision Medicine; Renal Insufficiency; Risk	2018
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. Journal of the American Society of Nephrology : JASN, 2014, Volume: 25, Issue:5 Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Endothelin-1; Female; Humans; Kidney Function Tests; Lipids; Male; Middle Aged; Pyrrolidines	2014
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clinical journal of the American Society of Nephrology : CJASN, 2015, Sep-04, Volume: 10, Issue:9 Topics: Aged; Albuminuria; Atrasentan; Body Fluids; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pyrrolidines; Weight Gain	2015
Comparison of exposure response relationship of atrasentan between North American and Asian populations. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:4 Topics: Aged; Albuminuria; Asia; Asian People; Atrasentan; Bilirubin; Body Fluids; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; North America; Pyrrolidines; Treatment Outcome; Weight Gain; White People	2017
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:4 Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Incidence; Male; Middle Aged; Pyrrolidines; Renin-Angiotensin System; Treatment Outcome	2011
Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life sciences, 2012, Oct-15, Volume: 91, Issue:13-14 Topics: Aged; Albuminuria; Atrasentan; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Edema; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Hispanic or Latino; Humans; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Renin-Angiotensin System	2012

Other Studies

19 other study(ies) available for atrasentan and Diabetic Nephropathies

Article	Year
Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease. Clinical journal of the American Society of Nephrology : CJASN, 2021, Volume: 16, Issue:12 Topics: Albuminuria; Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Humans; Pyrrolidines	2021
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease. Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:8 Topics: Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney; Liver; Renal Insufficiency, Chronic	2023
Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan. Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:8 Topics: Atrasentan; Biomarkers; Diabetic Nephropathies; Diuretics; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Heart Failure; Humans; Pyrrolidines	2023
Post hoc analysis of the SONAR trial: potential analgesic effects of atrasentan? Kidney international, 2023, Volume: 104, Issue:6 Topics: Atrasentan; Cognition; Diabetic Nephropathies; Humans; Pain; Prospective Studies	2023
Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply. Lancet (London, England), 2020, 01-25, Volume: 395, Issue:10220 Topics: Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Humans; Renal Insufficiency, Chronic	2020
SONAR: Do a New Design and Statistically Significant Results Translate to Reliability? Clinical journal of the American Society of Nephrology : CJASN, 2020, 06-08, Volume: 15, Issue:6 Topics: Atrasentan; Diabetic Nephropathies; Humans; Reproducibility of Results	2020
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy. American journal of physiology. Renal physiology, 2020, 05-01, Volume: 318, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Losartan; Mice; Phosphorylation; Podocytes; Proteinuria; Renin-Angiotensin System; Ribosomal Protein S6 Kinases; TOR Serine-Threonine Kinases	2020
Reduced Glomerular Endothelial Thrombomodulin Is Associated with Glomerular Macrophage Infiltration in Diabetic Nephropathy. The American journal of pathology, 2021, Volume: 191, Issue:5 Topics: Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Endothelium; Fibrosis; Humans; Inflammation; Kidney; Kidney Glomerulus; Macrophages; Male; Mice; Mice, Knockout; Thrombomodulin	2021
Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy. Clinical therapeutics, 2018, Volume: 40, Issue:2 Topics: Aged; Albuminuria; Atrasentan; Body Weight; Clinical Trials, Phase II as Topic; Creatinine; Diabetic Nephropathies; Double-Blind Method; Edema; Female; Humans; Kidney Function Tests; Male; Middle Aged; Randomized Controlled Trials as Topic	2018
[Diabetic Kidney Disease - How to Protect the Kidney?] Deutsche medizinische Wochenschrift (1946), 2019, Volume: 144, Issue:11 Topics: Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2019
Light of dawn in Melbourne: SONAR and CREDENCE. Kidney international, 2019, Volume: 96, Issue:1 Topics: Atrasentan; Australia; Canagliflozin; Clinical Trials as Topic; Congresses as Topic; Diabetic Nephropathies; Disease Progression; Endothelin A Receptor Antagonists; Humans; Kidney Failure, Chronic; Nephrology; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors	2019
Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy. Nature reviews. Nephrology, 2015, Volume: 11, Issue:2 Topics: Atrasentan; Cardiovascular Diseases; Diabetic Nephropathies; Endothelin Receptor Antagonists; Humans; Prognosis; Pyrrolidines	2015
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. Clinical journal of the American Society of Nephrology : CJASN, 2015, Mar-06, Volume: 10, Issue:3 Topics: Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrasentan; Bone Density Conservation Agents; Diabetic Nephropathies; Endothelin Receptor Antagonists; Ergocalciferols; Female; Fumarates; Humans; Losartan; Male; Middle Aged; Office Visits; Pyrrolidines; Randomized Controlled Trials as Topic; Research Design; Statistics as Topic; Urine Specimen Collection	2015
Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy. Scientific reports, 2016, Jan-27, Volume: 6 Topics: 3' Untranslated Regions; Albuminuria; Animals; Antioxidants; Atrasentan; Biomarkers; Cell Line; Diabetic Nephropathies; Disease Models, Animal; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation; Glucuronidase; Humans; Kidney Function Tests; Kidney Tubules; Klotho Proteins; Male; Mice; MicroRNAs; Middle Aged; Mitochondria; Promoter Regions, Genetic; Pyrrolidines; RNA Interference	2016
Diabetic nephropathy: Atrasentan stabilizes the endothelial glycocalyx. Nature reviews. Nephrology, 2016, Volume: 12, Issue:6 Topics: Albuminuria; Atrasentan; Diabetic Nephropathies; Endothelial Cells; Endothelium, Vascular; Glycocalyx; Humans; Pyrrolidines	2016
Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy. Diabetes, 2016, Volume: 65, Issue:8 Topics: Albuminuria; Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin Receptor Antagonists; Glomerular Filtration Rate; Kidney Glomerulus; Male; Mice; Mice, Knockout; Pyrrolidines	2016
Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel? Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:4 Topics: Albuminuria; Atrasentan; Diabetic Nephropathies; Endothelins; Glomerular Filtration Rate; Humans; Proteinuria; Pyridines; Pyrimidines; Pyrrolidines; Renin-Angiotensin System; Treatment Outcome	2011
Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. The Journal of pharmacology and experimental therapeutics, 2011, Volume: 338, Issue:1 Topics: Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Male; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Stereoisomerism; Sulfonamides	2011
Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. Journal of the American Society of Nephrology : JASN, 2007, Volume: 18, Issue:1 Topics: Animals; Atrasentan; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Inflammation; Kidney; Male; Oxidative Stress; Prostaglandins; Pyrrolidines; Rats; Rats, Sprague-Dawley; Superoxides	2007